Document is current
Any future updates will be listed below
-
Authors
Deiters, Viktoria https://orcid.org/0000-0002-9599-8672
Lorger, Anna
Eckardt, Franziska
Siedlecki, Jakob
Schworm, Benedikt
Priglinger, Siegfried G.
Herold, Tina R.
- License Information
-
More Information
Article History
Received: 16 March 2025
Accepted: 24 April 2025
First Online: 12 May 2025
Declarations
:
: The authors declare no competing interests related to this study. However, Tina R. Herold received previous speaker fees from Novartis Pharma GmbH, Bayer Vital GmbH, AbbVie Deutschland GmbH, Novo Nordisk Pharma GmbH, and Roche AG. Jakob Siedlecki received previous speaker fees from Roche AG, Apellis Pharmaceuticals, Novartis Pharma, Carl Zeiss Meditec, Bayer AG, AbbVie, and Heidelberg Engineering. Jakob Siedlecki received personal consultation fees from Roche AG, Bayer AG, Novartis Pharma GmbH, AbbVie, and Apellis Pharmaceuticals. Benedikt Schworm received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation. Siegfried G. Priglinger received previous speaker fees and travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharm GmbH, and Allergan GmbH. Viktoria Deiters, Franziska Eckardt and Anna Lorger declare no financial disclosures.
: The study adhered to the ethical guidelines of the Declaration of Helsinki, and institutional review board approval was obtained from the Ethics Committee of Ludwig-Maximilians-University Munich (study identifier 24-0638). Due to the retrospective nature of the study, Ethics Committee waived the need for obtaining informed consent.
